Considerations of antiviral treatment to interrupt mother-to-child transmission of hepatitis B virus in China. (10th May 2018)

• Record Type: Journal Article
• Authors: Cui, Fuqiang; Woodring, Joseph; Chan, Polin; Xu, Fujie
• Is Part Of: International journal of epidemiology. Volume 47:Number 5(2018)
• Page Start: 1529
• Page End: 1537
• Publication Date: 2018-05-10
• Subjects: hepatitis B -- mother-to-child transmission -- screening -- treatment; Epidemiology -- Periodicals; 614.4
• DOI: 10.1093/ije/dyy077
• Languages: English
• ISSNs: 0300-5771

Abstract

Abstract: Background: Treating high-risk women with antivirals in their third trimester is a promising intervention to further reduce perinatal transmission in neonates born to hepatitis B surface antigen positive [HBsAg(+)] mothers. Methods: We estimated the number of perinatal infections based on coverage and effectiveness of hepatitis B immunization. We compared cost-effectiveness of different approaches to identify high-risk women for antiviral treatment, by region and urban/rural residence. Results: Of the 16.59 million live births in 2015, 1.04 million infants (6.3%) were born to HBsAg(+) mothers and 268 201 infants (1.6%) to HBsAg(+) and HBeAg(+) dual-positive mothers. Despite immunoprophylaxis, 51 478 perinatal hepatitis B virus (HBV) transmissions were estimated to have occurred from HBsAg and HBeAg dual-positive mothers in 2015. Using HBeAg or HBV viral load testing to identify high-risk pregnant women and to treat them with Tenofovir, the incremental cost ranged from US$68.2 million to US$90.3 million. Assuming HBV viral load testing is available and used to guide treatment and all women with HBV viral loads >200 000 IU/ml are treated, 25 912 infections would be averted at a projected cost of US$3500 per infection averted. Conclusions: Identifying high-risk pregnant women and providing them with antiviral treatment is feasible and cost-effective to interrupt perinatal HBV transmissions. Policy options should be urgently explored in order for China to reach the HBV elimination goal of 0.1% prevalence among children by 2030.